Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06892288 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG
A Phase 2 study of Phosphomannomutase 2 Deficiency and PMM2-CDG, sponsored by Glycomine.
- Active
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 15
- Study locations
NCT06892288: Active Phase 2 study of Phosphomannomutase 2 Deficiency and PMM2-CDG, sponsored by Glycomine.
NCT06892288 is a Phase 2 study of Phosphomannomutase 2 Deficiency and PMM2-CDG that is active but no longer recruiting, run by Glycomine. The registered enrollment target is 50 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower). The trial reports 15 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06892288, a Phase 2 study of Phosphomannomutase 2 Deficiency and PMM2-CDG, is active but no longer recruiting, sponsored by Glycomine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 15
- Study locations
Study Summary
This study is evaluating the safety, effectiveness, and how the body absorbs, distributes, and eliminates GLM101, for participants with PMM2-CDG, including children, adolescents, and adults. Researchers will compare participants receiving GLM101 to those receiving a placebo to see if GLM101 improves symptoms of PMM2-CDG. The study includes two treatment parts: a 24-week double blind placebo-controlled treatment period (Part A), and a 24-week open-label phase where every participant will receive GLM101(Part B).
Primary Outcome
To characterize the change from Baseline in ataxia at 24 weeks, comparing GLM101 to placebo in participants with PMM2-CDG as assessed by ICARS. The scale is scored out of 100 with 19 items and four subscales of postural and gait disturbances, limb ataxia, dysarthria, and oculomotor disorders. Higher scores indicate higher levels of impairment (Part A).
Conditions Studied
Interventions
- DRUG GLM101 (Part A, Double-blind)
- DRUG Placebo (Part A, Double-blind)
- DRUG GLM101 (Part B, Open-label)
Study Locations (15)
Other
- UZ Leuven, Campus Gasthuisberg - Leuven
- Vseobecna fakultni nemocnice v Praze - Prague
- AP-HP Hopital Necker-Enfants Malades - Paris
- Universitaetsklinikum Muenster - Münster
- Azienda Ospedaliero Universitaria Policlinico G. Rodolico-San Marco - Catania
- Azienda Ospedaliero Universitaria Pisana - Pisa
- Instytut Matki i Dziecka - Warsaw
- Unidade Local de Saúde de Santo António - Porto
- Hospital Sant Joan de Déu - Esplugues de Llobregat
- Hospital Universitario 12 de Octubre - Madrid
- Birmingham Women's and Children's NHS Foundation Trust - Birmingham
Minnesota
- University of Minnesota - Minneapolis
New York
- Icahn School of Medicine at Mount Sinai - New York
Pennsylvania
- The Children's Hospital of Philadelphia - Philadelphia
Washington
- Seattle Children's Hospital - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-07-09 |
| Est. Completion | 2027-04-30 |
| Phase | Phase 2 |
What the registry record for NCT06892288 still lists
NCT06892288 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower).
The record links to 2 conditions, with Phosphomannomutase 2 Deficiency appearing as the primary indexed condition, and to 3 interventions - of which GLM101 (Part A, Double-blind) is the first listed.
NCT06892288 lists 15 locations in 5 states (Other, Minnesota, New York).
Frequently Asked Questions
What is clinical trial NCT06892288 about?
NCT06892288 is a clinical study titled "A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG". This study is evaluating the safety, effectiveness, and how the body absorbs, distributes, and eliminates GLM101, for participants with PMM2-CDG, including children, adolescents, and adults. Researchers will compare participants receiving GLM101 to those receiving a placebo to see if GLM101 improves...
What is the current status of trial NCT06892288?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2025-07-09. Estimated completion is 2027-04-30.
What conditions does trial NCT06892288 study?
This clinical trial studies the following conditions: Phosphomannomutase 2 Deficiency, PMM2-CDG.
What interventions are being tested in trial NCT06892288?
The interventions under investigation include: GLM101 (Part A, Double-blind) (DRUG), Placebo (Part A, Double-blind) (DRUG), GLM101 (Part B, Open-label) (DRUG).
Who is sponsoring clinical trial NCT06892288?
This trial is sponsored by Glycomine, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06892288 being conducted?
This trial has 15 study locations across Minnesota, New York, Pennsylvania, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Phosphomannomutase 2 Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06892288's enrollment target sits among peer trials
50 1195th of 2000 higher than 740 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI